| Evolution of cell therapy for renal cell carcinoma Y Wang, ER Suarez, G Kastrunes, NSP de Campos, R Abbas, RS Pivetta, ... Molecular Cancer 23 (1), 8, 2024 | 21 | 2024 |
| Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects Y Wang, A Buck, B Piel, L Zerefa, N Murugan, CD Coherd, AG Miklosi, ... Molecular Cancer 23 (1), 56, 2024 | 9 | 2024 |
| fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects Y Wang, A Buck, G Kastrunes, R Abbas, M Lynch, Z Zhong, SM Hoang, ... Cancer Research 83 (7_Supplement), 886-886, 2023 | 1 | 2023 |
| 582 Spatial profiling reveals architecture difference between primary and lung metastatic ccRCC Y Wang, JW Cho, YN Laimon, AB Sheshdeh, N Murugan, HC Yuan, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| Establishing orthotopic renal cell carcinoma xenograft in PBMC-humanized immunodeficient NSG-MHC I/II double knock-out mice W Kang, Y Wang, YN Laimon, O Pham, B Matran, L Bottoms, S Khang, ... Cancer Research 84 (6_Supplement), 111-111, 2024 | | 2024 |
| Fine-tuning affinity/avidity of anti-CAIX CAR T cells to mitigate on-target off-tumor toxicity in clear cell renal cell carcinoma SHC Yuan, Y Wang, R Abbas, P Mathenge, C Chien, CD Coherd, ... Cancer Research 84 (6_Supplement), 4004-4004, 2024 | | 2024 |
